Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction

Early Phase 1CompletedNCT05244694

University of Missouri-Columbia28 enrolled

Overview

The purpose of this project is to determine if hyperinsulinemia attenuates sympathetic nervous system-mediated vasoconstriction in the human leg.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Vasoconstriction Healthy Insulin Resistance

Interventions

InsulinDRUG

Priming dose then a constant infusion at 40 mU•m-2•min-1

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy adult men and women; * 18-45 years of age; * BMI 18-30 kg/m2; * non-pregnant/non-breastfeeding; * non-nicotine users; Exclusion Criteria: * taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic functions Self-reported history of: * hepatic, renal, pulmonary, cardiovascular, or neurological disease; * stroke or neurovascular disease; * bleeding/clotting disorders; * sleep apnea or other sleep disorders; * diabetes; * smoking; * history of alcoholism or substance abuse, excessive alcohol consumption; * hypertension; * active cancer; * autoimmune disease; * immunosuppressant therapy

Locations (1)

University of Missouri

Columbia, Missouri, United States

Outcomes

Primary Outcomes

Amount of leg blood flow

Measured with Doppler ultrasound (mL/min)

Time frame: Change from baseline at minute 60

Secondary Outcomes

Amount of muscle sympathetic nerve activity (MSNA)

MSNA burst incidence (bursts/100 heart beats)

Time frame: Change from baseline at minute 60

Amount of cerebral blood flow

Measured with trans-cranial Doppler ultrasound (cm/s)

Time frame: Change from baseline at minute 60

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.